Evotec SE - Asset Resilience Ratio
Evotec SE (EVT) has an Asset Resilience Ratio of 3.47% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check EVT strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2025)
This chart shows how Evotec SE's Asset Resilience Ratio has changed over time. See Evotec SE balance sheet independence to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Evotec SE's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see EVT stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €56.85 Million | 3.47% |
| Total Liquid Assets | €56.85 Million | 3.47% |
Asset Resilience Insights
- Limited Liquidity: Evotec SE maintains only 3.47% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Evotec SE Industry Peers by Asset Resilience Ratio
Compare Evotec SE's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Evotec SE (2003–2025)
The table below shows the annual Asset Resilience Ratio data for Evotec SE.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 26.78% | €476.39 Million ≈ $556.95 Million |
€1.78 Billion ≈ $2.08 Billion |
+6.03pp |
| 2024-12-31 | 20.75% | €396.80 Million ≈ $463.90 Million |
€1.91 Billion ≈ $2.24 Billion |
-6.07pp |
| 2023-12-31 | 26.82% | €604.11 Million ≈ $706.27 Million |
€2.25 Billion ≈ $2.63 Billion |
-5.52pp |
| 2022-12-31 | 32.34% | €729.98 Million ≈ $853.43 Million |
€2.26 Billion ≈ $2.64 Billion |
-6.07pp |
| 2021-12-31 | 38.41% | €858.50 Million ≈ $1.00 Billion |
€2.24 Billion ≈ $2.61 Billion |
+4.73pp |
| 2020-12-31 | 33.68% | €492.63 Million ≈ $575.94 Million |
€1.46 Billion ≈ $1.71 Billion |
+6.44pp |
| 2019-12-31 | 27.24% | €321.66 Million ≈ $376.06 Million |
€1.18 Billion ≈ $1.38 Billion |
+7.82pp |
| 2018-12-31 | 19.42% | €149.88 Million ≈ $175.22 Million |
€771.88 Million ≈ $902.41 Million |
+4.19pp |
| 2017-12-31 | 15.22% | €101.58 Million ≈ $118.75 Million |
€667.27 Million ≈ $780.11 Million |
-21.17pp |
| 2016-12-31 | 36.39% | €127.86 Million ≈ $149.48 Million |
€351.37 Million ≈ $410.78 Million |
+5.04pp |
| 2015-12-31 | 31.35% | €90.46 Million ≈ $105.76 Million |
€288.54 Million ≈ $337.33 Million |
+13.01pp |
| 2014-12-31 | 18.35% | €41.21 Million ≈ $48.17 Million |
€224.60 Million ≈ $262.58 Million |
-4.74pp |
| 2013-12-31 | 23.09% | €52.49 Million ≈ $61.37 Million |
€227.38 Million ≈ $265.83 Million |
+11.30pp |
| 2012-12-31 | 11.79% | €26.57 Million ≈ $31.07 Million |
€225.43 Million ≈ $263.55 Million |
-9.30pp |
| 2011-12-31 | 21.08% | €46.01 Million ≈ $53.79 Million |
€218.21 Million ≈ $255.11 Million |
-3.65pp |
| 2010-12-31 | 24.73% | €47.45 Million ≈ $55.47 Million |
€191.86 Million ≈ $224.30 Million |
+7.38pp |
| 2009-12-31 | 17.35% | €25.43 Million ≈ $29.73 Million |
€146.60 Million ≈ $171.39 Million |
+1.47pp |
| 2008-12-31 | 15.87% | €29.03 Million ≈ $33.94 Million |
€182.90 Million ≈ $213.83 Million |
-12.09pp |
| 2007-12-31 | 27.97% | €58.14 Million ≈ $67.97 Million |
€207.88 Million ≈ $243.03 Million |
+17.98pp |
| 2006-12-31 | 9.99% | €20.53 Million ≈ $24.00 Million |
€205.53 Million ≈ $240.28 Million |
-40.25pp |
| 2005-12-31 | 50.24% | €93.50 Million ≈ $109.31 Million |
€186.11 Million ≈ $217.58 Million |
-34.42pp |
| 2004-12-31 | 84.66% | €60.03 Million ≈ $70.18 Million |
€70.91 Million ≈ $82.90 Million |
+9.14pp |
| 2003-12-31 | 75.52% | €31.51 Million ≈ $36.84 Million |
€41.73 Million ≈ $48.78 Million |
-- |
About Evotec SE
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more